You are here

  • Home
  • Archive
  • Volume 5, Issue 6
  • Hospitalisation for more than 3 days after thrombolysis for uncomplicated myocardial infarction was not cost effective

Article Text

Article menu
Download PDFPDF
Economics
Hospitalisation for more than 3 days after thrombolysis for uncomplicated myocardial infarction was not cost effective

https://doi.org/10.1136/ebm.5.6.190

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2000) N Engl J Med 342, 749. Newby LK, Eisenstein EL, Califf RM. , et al. . Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. . . Mar 16;. :. –55..
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: For patients who have had a low risk myocardial infarction (MI), is early discharge on day 3 instead of day 4 after thrombolysis safe and cost effective?

    Design

    Decision analytic model using data from a randomised controlled trial (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries [GUSTO-1]).

    Setting

    {1081 hospitals in 15 countries}*.

    Patients

    38 911 of 41 021 enrolled patients who presented with a confirmed MI 20 minutes to 6 hours after symptom onset and who had an uncomplicated course (absence of death, reinfarction, congestive heart failure, recurrent ischaemia, stroke, shock, emergency angiography or angioplasty, bypass surgery, intra-aortic balloon pumping, cardioversion, or defibrillation). Exclusion criteria were angiographic 3 vessel or left main coronary artery disease or elective bypass surgery >3 days after thrombolysis.

    Intervention

    Discharge at day 3 compared …

    View Full Text

    Footnotes

    • Sources of funding: Bayer; CIBA-Corning; Genentech; ICI Pharmaceuticals; Sanofi Pharmaceuticals.

    • For correspondence: Dr L K Newby, Duke Clinical Research Institute, PO Box 17969, Durham NC 27715-7969, USA. Fax +1 919 668 7059.

    • ↵* The GUSTO Investigators. N Engl J Med 1993;329: 673–82.